Evidence map›Paper›PMID 39483850›Full record

ArticleFrontiers in genetics2024

ONT sequencing identifies a high prevalence of

Adebanjo Jonathan Adegbola, Leonard Ndwiga, Kevin Wamae, Victor Osoti, Oluseye Oladotun Bolaji, Philip Bejon, Lynette Isabella Ochola-Oyier

Abstract read
In one paragraph

Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adebanjo Jonathan AdegbolaFaculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
Leonard NdwigaKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Kevin WamaeKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Victor OsotiKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Oluseye Oladotun BolajiFaculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.
Philip BejonKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Lynette Isabella Ochola-OyierKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.

Funding

Gates Foundation INV-036442Wellcome Trust
6 · The paper itself

Abstract

Background: Malaria in pregnancy is a major public health issue, particularly among vulnerable populations in malaria-endemic sub-Saharan African countries. To mitigate its risks, WHO recommends sulphadoxine-pyrimethamine (SP) for chemoprevention and artemisinin-based combination therapy (ACT) to treat uncomplicated Methods: Dried blood spots (DBS) were collected from pregnant women who received IPTp-SP at the enrollment and follow-up visits. Result: In total, 251 pregnant women were enrolled in the study and 457 DBS samples were collected. Conclusion and recommendations: Here a multiplexed amplicon-based ONT assay established that triple mutant

Indexed as

chemoprevensiongenotypingmalariaresistancesequencingsurveillance

Identifiers

PMID39483850
PMCPMC11525066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.